All articles tagged with #multi target therapy
Alzheimer’s is viewed as a complex system driven by amyloid-beta and tau, aging, and systemic health; single-target drugs have limited impact, so researchers are pushing integrated, multi-pronged therapies—combining approaches like gene editing, senolytics, metabolic interventions, and gut-brain axis strategies—guided by early biomarkers and advanced models to slow, halt, or prevent disease progression.
A new Science China Life Sciences review argues that Alzheimer’s arises from a complex network of factors—amyloid and Tau pathology, genetics, aging, and systemic health—making single-target drugs insufficient. The authors urge a holistic strategy that tackles multiple disease pathways, including Tau and aging-related changes, genetic risk, and gut-brain interactions, while leveraging tools like iPSC-derived organoids, CRISPR, and early biomarkers (e.g., plasma pTau217) to guide precision therapies and possibly delay or prevent progression.